Assessing the Effectiveness of Pharmacy-Based Adherence Interventions on Antiretroviral Adherence in Persons with HIV
Publication: AIDS Patient Care and STDs
Volume 25, Issue Number 4
Abstract
A key factor to the successful treatment of HIV is good adherence to antiretroviral therapy (ART). We developed a pharmacist-managed adherence clinic and designed a study to assess the impact of the adherence interventions by measuring the proportion of patients with 95% or greater adherence to ART before and after referral to the program. HIV providers referred patients with adherence problems to a pharmacist-managed adherence clinic. Interventions included scheduled clinic visits with the HIV Clinical Pharmacist and monthly refill reminders from pharmacy staff members over a 6-month period. Those aged 18–75, prescribed an ART regimen for a minimum of 3 months, and who filled their medications exclusively at the clinic pharmacy were eligible for study participation. The Proportion of Days Covered (PDC) served as a surrogate marker of overall adherence. A total of 34 patients were referred to the pharmacy clinic for adherence counseling, of whom 28 enrolled in the study. The proportion of participants with 95% or greater adherence to their ART regimen increased from 7% at baseline to 32% postintervention (p = 0.01). A subanalysis of the PDC revealed an overall increase from a baseline adherence mean of 60% to 81% postintervention (p < 0.0001). There was a notable trend toward an increase in the proportion of participants with an undetectable HIV-1 viral load (58–73%, baseline and postintervention, respectively, p = 0.10), but no statistically significant improvement in CD4 cell count. Clinical pharmacy interventions improved overall adherence to ART regimens in these patients with HIV.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Kitahata MMReed SDDillingham PW et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and deathInt J STD AIDS200415803-810. 1. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004;15:803–810.
2.
Golin CELiu HHays RD et al. A prospective study of predictors of adherence to combination antiretroviral medicationJ Gen Intern Med200217756-765. 2. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756–765.
3.
Atkinson MJPetrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medicationsAIDS Patient Care and STDs200923903-914. 3. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care and STDs 2009;23:903–914.
4.
Paterson DLSwindells SMohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med200013321-30. 4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21–30.
5.
Arnsten JHDemas PAGrant RW et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug usersJ Gen Intern Med200217377-381. 5. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377–381.
6.
Bangsberg DRHecht FMCharlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent populationAIDS200014357-366. 6. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357–366.
7.
Maggiolo FRavasio LRipamonti D et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitorsClin Infect Dis200540158-163. 7. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40:158–163.
8.
Gulick RM. Adherence to antiretroviral therapy: How much is enough?Clin Infect Dis200643942-944. 8. Gulick RM. Adherence to antiretroviral therapy: How much is enough? Clin Infect Dis 2006;43:942–944.
9.
Gross RYip BWood E et al. Boosted protease inhibitors are more forgiving of suboptimal adherence than non-boosted protease inhibitors or nonucleoside reverse transcriptase inhibitors [Abstract 533]Denver, CO13th Conference on Retroviruses and Opportunistic InfectionsFebruary5–82006. 9. Gross R, Yip B, Wood E, et al. Boosted protease inhibitors are more forgiving of suboptimal adherence than non-boosted protease inhibitors or nonucleoside reverse transcriptase inhibitors [Abstract 533]. Denver, CO: 13th Conference on Retroviruses and Opportunistic Infections, February 5–8, 2006.
10.
Shuter JSarlo JAKanmaz TJRode RAZingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%J Acquir Immune Defic Syndr2007454-8. 10. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4–8.
11.
McKinnel JAWillig JHWestfall AO et al. Antiretroviral prescribing patterns in treatment-naïve patients in the United StatesAIDS Patient Care STDs20102479-8511. McKinnel JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naïve patients in the United States. AIDS Patient Care STDs 2010;24:79–85
12.
Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapyJ Antimicrob Chemother200861769-773. 12. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769–773.
13.
Bisson GPRowh AWeinstein R et al. Antiretroviral failure despite high levels of adherence: Discordant adherence-response relationship in BotswanaJ Acquir Immune Defic Syndr200849107-110. 13. Bisson GP, Rowh A, Weinstein R, et al. Antiretroviral failure despite high levels of adherence: Discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 2008;49:107–110.
14.
Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppressionClin Infect Dis200643939-941. 14. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939–941.
15.
Lima VDHarrigan RMurray M et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individualsAIDS2008222371-2380. 15. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008;22:2371–2380.
16.
Simoni JMKurth AEPearson CRPantalone DWMerrill JOFrick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical managementAIDS Behav200610227-245. 16. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006;10:227–245.
17.
Nieuwkerk PTOort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysisJ Acquir Immune Defic Syndr200538445-448. 17. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. J Acquir Immune Defic Syndr 2005;38:445–448.
18.
Liechty CAAlexander CSHarrigan PR et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior?AIDS200418127-129. 18. Liechty CA, Alexander CS, Harrigan PR, et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS 2004;18:127–129.
19.
Wood EHogg RSYip BHarrigan PRO'Shaughnessy MVMontaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/LAnn Intern Med.2003139810-816. 19. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139:810–816.
20.
Sclar DAChin ASkaer TLOkamoto MPNakahiro RKGill MA. Effect of health education in promoting prescription refill compliance among patients with hypertensionClin Ther199113489-495. 20. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991;13:489–495.
21.
Yang YThumula VPace PFBanahan BF 3rdWilkin NELobb WB. Nonadherence to angiotensinconverting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programsJ Am Pharm Assoc200350527-531. 21. Yang Y, Thumula V, Pace PF, Banahan BF, 3rd, Wilkin NE, Lobb WB. Nonadherence to angiotensinconverting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs. J Am Pharm Assoc 2003;50:527–531.
22.
Cambiano VLampe FCRodger AJ et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppressionHIV Med201011216-224. 22. Cambiano V, Lampe FC, Rodger AJ, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med 2010;11:216–224.
23.
Mannheimer SBMorse EMatts JP et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trialJ Acquir Immune Defic Syndr200643Suppl 1S41-47. 23. Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S41–47.
24.
Guerrault MNLeclerc CLangevin SMerian-Brosse LBrossard DWelker Y. [Study of the usefulness of pharmacist consultations for patients on antiretroviral regimens]Presse Med2005341563-1570. 24. Guerrault MN, Leclerc C, Langevin S, Merian-Brosse L, Brossard D, Welker Y. [Study of the usefulness of pharmacist consultations for patients on antiretroviral regimens]. Presse Med 2005;34:1563–1570.
25.
Cantwell-McNelis KJames CW. Role of clinical pharmacists in outpatient HIV clinicsAm J Health Syst Pharm200259447-452. 25. Cantwell-McNelis K, James CW. Role of clinical pharmacists in outpatient HIV clinics. Am J Health Syst Pharm 2002;59:447–452.
26.
Improving the prevention and treatment of HIV/AIDS through pharmacist interventionsGal DThe International Network for Pharmacists on HIV/AIDSInternational Pharmaceutical Federation (FIP)2004. 26. Improving the prevention and treatment of HIV/AIDS through pharmacist interventions. In: Gal D, ed. The International Network for Pharmacists on HIV/AIDS: International Pharmaceutical Federation (FIP), 2004.
27.
Knobel HCarmona ALopez JL et al. [Adherence to very active antiretroviral treatment: Impact of individualized assessment]Enferm Infecc Microbiol Clin19991778-81. 27. Knobel H, Carmona A, Lopez JL, et al. [Adherence to very active antiretroviral treatment: Impact of individualized assessment]. Enferm Infecc Microbiol Clin 1999;17:78–81.
28.
McPherson-Baker SMalow RMPenedo FJones DLSchneiderman NKlimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive menAIDS Care200012399-404. 28. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000;12:399–404.
29.
Simoni JMFrick PAPantalone DWTurner BJ. Antiretroviral adherence interventions: A review of current literature and ongoing studiesTop HIV Med200311185-198. 29. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: A review of current literature and ongoing studies. Top HIV Med 2003;11:185–198.
30.
VAMC. Pharmacist Counseling, use of compliance tool: Does it improve outcomes in an HIV population?Formulary1998331144. 30. VAMC. Pharmacist Counseling, use of compliance tool: Does it improve outcomes in an HIV population? Formulary 1998;33:1144.
31.
Atkinson MJPetrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medicationsAIDS Patient Care STDs200923903-914. 31. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDs 2009;23:903–914.
32.
Hirsch JDRosenquist ABest BMMiller TAGilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiariesJ Manag Care Pharm20091532-41. 32. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm 2009;15:32–41.
33.
Rueda SPark-Wyllie LYBayoumi A et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDSThe Cochrane Database Syst Rev20063CD001442. 33. Rueda S, Park-Wyllie LY, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. The Cochrane Database Syst Rev 2006;3:CD001442.
34.
Hugen PWBurger DMKoopmans PP et al. Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfastPharm World Sci20022483-86. 34. Hugen PW, Burger DM, Koopmans PP, et al. Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci 2002;24:83–86.
35.
Pellegrin IBreilh DMontestruc F et al. Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study)AIDS2002161331-1340. 35. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002;16:1331–1340.
36.
Zhou XJHavlir DVRichman DD et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1–infected patientsAIDS2000142869-2876. 36. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1–infected patients. AIDS 2000;14:2869–2876.
37.
Ma AChen DMChau FMSaberi P. Improving adherence and clinical outcomes through an HIV pharmacist's interventionsAIDS Care20101-6. 37. Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 2010:1–6.
Information & Authors
Information
Published In
Copyright
Copyright 2011, Mary Ann Liebert, Inc.
History
Published in print: April 2011
Published online: 31 March 2011
Published ahead of print: 16 February 2011
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.